Interview: Gerhard Hirczi – Managing Director, Vienna Business Agency; Peter Halwachs – Managing Director, LISAvienna

06.11.2017
Gerhard Hirczi of the Vienna Business Agency and Peter Halwachs of LISAvienna describe Vienna’s impressive footprint in the life sciences, its positioning as the start-up hub for Central and Eastern Europe, and the potential ramifications of the European Medicines Agency (EMA) relocating to the city. Could you please start by introducing the Vienna Business Agency and its functions?
"The time has come for the international community to reevaluate Vienna’s role in the pharmaceuticals and life sciences landscape."
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Austria, Vienna Business Agency, LISAvienna, Investment, R&D

Related Interviews

Interview: Alexander Biach – Chairman, Hauptverband (Main Association of…

Alexander Biach, chairman of the Main Association of Austrian Social Security Institutions, discusses handling the responsibility for Austria’s Europe-leading social security coverage, current inefficiencies that need to be ironed out,…

Interview: Albin Egger – Country Representative, UCB Pharma Austria

Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian affiliate within the global group, organizational restructuring, and the receptiveness of Austria to UCB’s innovative…

Interview: Joy Ladurner – Co-Director, NKSE, Austria

Joy Ladurner, co-director of the NKSE (National Coordination Center for Rare Diseases) in Austria, discusses the rationale behind Austria’s prioritization of rare diseases and its leading role in the field.…

Related Articles

Europe / Sandoz Bolsters its Essential Medicine Manufacturing Capacity

In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz – the generics arm of global giant Novartis – has moved…

Austria: Nucleus of Clinical Trials

Like a family recipe that has been refined and perfected over countless generations, Austria has developed a reputation as the quintessential clinical trials destination; a perfect combination of world-class academia,…

Austria: Orchestrating Innovation

Austria has long been merely a cog in the wheel of global R&D, lying in the shadows of neighboring research giants, Germany and Switzerland. Now, however, this perception is changing…

Latest Report

Saudi Arabia Pharma Report 2022

Related Content

Austria
Vienna Business Agency
LISAvienna
Investment
R&D